UP!

BIIB $275.17   View long term graphs

Biogen
Type
Public
Traded as
  • NASDAQ: BIIB
  • NASDAQ-100 Component
  • S&P 100 Component
  • S&P 500 Component
Industry Biotechnology
Founded 1978 (from merger)
Founders Kenneth Murray
Phillip Allen Sharp
Walter Gilbert
Heinz Schaller
Charles Weissmann
Headquarters Cambridge, Massachusetts, U.S.
Key people
Stelios Papadopoulos, Chairman
Michel Vounatsos, CEO
Products Alprolix, Avonex, Eloctate, Fampyra, Gazyva*, Plegridy, Rituxan*, Tecfidera, Tysabri, Spinraza
Revenue Increase US$ 10.76 billion (2015) <
Operating income
Increase US$ 4.89 billion (2015)
Net income
Increase US$ 3.55 billion (2015)
Total assets Increase US$ 19.505 billion (2015)
Total equity Decrease US$ 9.37 billion (2014)
Number of employees
7,350 (December 2015)
Website www.biogen.com

Biogen, Inc. (previously known as Biogen Idec) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

Biogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase), Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich (who contributed the first product interferon alpha). Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.

In 2003, Biogen merged with San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston, Howard Birndorf and Robert E. Sobol) and adopted the name Biogen Idec. After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world. Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB.

In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million. Later in the same month, the company announced its intention to acquire Fumapharm AG, consolidating ownership of Fumaderm and BG-12, an oral fumarate, which is being studied for the treatment of multiple sclerosis and psoriasis.

In January 2007, the company announced it would acquire Syntonix Pharmaceuticals for up to $120 million, gaining Syntonix's lead product for hemophilia B as well as the technology for developing inhalable treatments.

In February 2013, Bloomberg broke the news that Biogen was planning the pay Elan $3.25 billion for the full rights to Tysabri, used to treat multiple sclerosis.

In January 2015 the company announced it will acquire Convergence Pharmaceuticals for up to $675 million, with the acquisition aiming to accelerate the development of Convergence's pipeline, in-particular CNV1014802 – a Phase II small molecule sodium channel blocking candidate. In October 2015 the company announced it will lay off 11% of its workforce, effective immediately.

In May 2016 the company announced that it will spin off its hemophilia drug business (Eloctate and Alprolix) into a public company. In August, the company announced that the spun off company would be called Bioverativ, in order to show heritage with Biogen. The company will trade on the NASDAQ exchange under the ticker symbol BIVV and will look to be spun off in early 2017.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Biogen
(Founded 1978)

IDEC Pharmaceuticals

Conforma Therapeutics
(Acq 2006)

Fumapharm AG
(Acq 2006)

Syntonix Pharmaceuticals
(Acq 2007)

Convergence Pharmaceuticals
(Acq 2015)

Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX.

Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by Acorda Therapeutics.

Acquired in acquisition of Fumapharm AG in 2006.

Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.

Anti-TNF Refractory Rheumatoid Arthritis

ANCA-Associated Vasculitis

Chronic lymphocytic leukemia

2006

2011

Currently commercialized by Roche and its subsidiary, Genentech.

Biogen has focused its R&D efforts on the discovery and development of treatments for patients with high unmet medical needs in the areas of neurology, hematology and immunology.

Investigational MS medicines:

Biogen has several candidates in Phase 1 and 2 clinical trials in neurodegenerative and immunological diseases including MS, Alzheimer’s disease, neuropathic pain, spinal muscular atrophy and lupus nephritis:

Biogen also has several development agreements in place with Ionis Pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders.

In February 2012, Biogen formalized a joint venture with Samsung, creating Samsung Bioepis. This joint venture brings Biogen’s expertise and capabilities in protein engineering, cell line development, and recombinant biologics manufacturing to position the joint venture so Biogen can participate in the emerging market for biosimilars.

In early 2014, Biogen entered into an agreement with Eisai, Inc., to jointly develop and commercialize two of their candidates for Alzheimer’s disease, which have the potential to reduce Aβ plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression.

Biogen also has since 2015 an agreement with AGTC for the development of gene therapy for opthalmologic deseases such as X-linked retinoschisis (XLRS) and X-linked Retinitis pigmentosa (XLRP), and up to three other genetice desases. To this aim, Biogen paid AGTC $124 million, including an equity investment of $30 millions, and up to 1,1 billion in future milestones.

Coordinates: 42°21′58.3″N 71°5′13.2″W / 42.366194°N 71.087000°W / 42.366194; -71.087000

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-01-28 Future report Set alerts
Q3 2020 2020-10-20 Future report Set alerts
Q2 2020 2020-07-22 10.26 9.59
Q1 2020 2020-04-22 9.14 8.08
Q4 2019 2020-01-30 8.34 8.08
Q3 2019 2019-10-22 9.17 8.39
Q2 2019 2019-07-23 9.15 7.85
Q1 2019 2019-04-24 6.98 7.15
Q4 2018 2019-01-29 6.99 4.73
Q3 2018 2018-10-23 7.40 7.15

Ratings

2016-07-13 Reiterated Rating Jefferies Group Buy
2016-06-30 Reiterated Rating Morgan Stanley Buy
2016-06-30 Reiterated Rating Jefferies Group Buy
2016-06-30 Reiterated Rating Leerink Swann Hold
2016-06-30 Reiterated Rating Bank of America Buy
2016-06-30 Reiterated Rating Bank of America Corp. Buy
2016-06-29 Initiated Coverage Sanford C. Bernstein Outperform $282.00
2016-06-22 Reiterated Rating Robert W. Baird Neutral $268.00
2016-06-08 Reiterated Rating RBC Capital Buy
2016-06-08 Reiterated Rating HC Wainwright Buy $360.00
2016-06-08 Reiterated Rating Wells Fargo Buy
2016-06-08 Reiterated Rating BMO Capital Markets Market Perform $287.00
2016-06-08 Reiterated Rating Royal Bank Of Canada Buy
2016-06-08 Reiterated Rating Wells Fargo & Co. Buy
2016-06-07 Reiterated Rating Piper Jaffray Hold $293.00
2016-06-07 Reiterated Rating Leerink Swann Market Perform $319.00
2016-06-07 Downgrade Citigroup Inc. Buy to Neutral $345.00 to $295.00
2016-06-07 Reiterated Rating Piper Jaffray Cos. Hold $293.00
2016-06-01 Reiterated Rating Leerink Swann Market Perform $319.00
2016-05-29 Reiterated Rating Jefferies Group Buy
2016-05-26 Reiterated Rating Cowen and Company Buy
2016-05-16 Reiterated Rating Robert W. Baird Hold
2016-05-03 Reiterated Rating Leerink Swann Positive $319.00
2016-05-03 Reiterated Rating Piper Jaffray Hold
2016-04-25 Reiterated Rating Leerink Swann Market Perform $328.00 to $319.00
2016-04-24 Reiterated Rating Jefferies Group Buy
2016-04-23 Reiterated Rating Goldman Sachs Hold
2016-04-23 Reiterated Rating Goldman Sachs Group Inc. Hold
2016-04-21 Reiterated Rating Piper Jaffray Hold
2016-04-21 Boost Price Target Goldman Sachs Neutral $271.00 to $285.00
2016-04-21 Reiterated Rating Stifel Nicolaus Hold
2016-04-18 Reiterated Rating Leerink Swann Hold
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-04-15 Reiterated Rating Robert W. Baird Hold
2016-04-12 Reiterated Rating Leerink Swann Market Perform $328.00
2016-04-11 Reiterated Rating Citigroup Inc. Buy $345.00
2016-04-08 Lower Price Target Morgan Stanley $419.00 to $404.00
2016-04-06 Lower Price Target Jefferies Group Buy $325.00
2016-04-05 Initiated Coverage BMO Capital Markets Market Perform $283.00
2016-03-28 Reiterated Rating Leerink Swann Market Perform $335.00 to $328.00
2016-03-23 Reiterated Rating Jefferies Group Buy $338.00
2016-03-16 Reiterated Rating Leerink Swann Market Perform $335.00
2016-03-11 Reiterated Rating Robert W. Baird Neutral $292.00 to $268.00
2016-02-25 Initiated Coverage Citigroup Inc. Buy $345.00
2016-02-22 Lower Price Target Goldman Sachs $293.00 to $272.00
2016-02-18 Reiterated Rating HC Wainwright Buy $360.00
2016-02-06 Reiterated Rating Leerink Swann Hold
2016-02-04 Initiated Coverage Leerink Swann Market Perform $335.00
2016-02-01 Reiterated Rating HC Wainwright Buy $360.00
2016-01-28 Reiterated Rating Jefferies Group Buy
2016-01-27 Reiterated Rating JPMorgan Chase & Co. Overweight $403.00
2016-01-27 Reiterated Rating William Blair Outperform
2016-01-27 Reiterated Rating Cowen and Company Buy
2016-01-27 Reiterated Rating Piper Jaffray Neutral $293.00
2016-01-22 Reiterated Rating Barclays Buy $420.00
2016-01-22 Reiterated Rating Wells Fargo Outperform
2016-01-22 Reiterated Rating Barclays PLC Buy $420.00
2016-01-19 Initiated Coverage Credit Suisse Neutral $322.00
2016-01-19 Initiated Coverage Credit Suisse Group AG Neutral $322.00
2016-01-12 Reiterated Rating JPMorgan Chase & Co. Overweight
2016-01-07 Initiated Coverage Standpoint Research Buy $360.00
2016-01-04 Reiterated Rating Cowen and Company Buy $368.00
2015-12-18 Initiated Coverage Atlantic Securities Overweight $344.00
2015-12-03 Initiated Coverage Wells Fargo Outperform
2015-12-01 Reiterated Rating Raymond James Buy $104.00
2015-12-01 Reiterated Rating Raymond James Financial Inc. Buy $104.00
2015-11-19 Reiterated Rating Jefferies Group Buy $322.00
2015-11-05 Upgrade Piper Jaffray Neutral to Overweight
2015-10-22 Reiterated Rating Leerink Swann Outperform $425.00
2015-10-22 Reiterated Rating Cowen and Company Outperform $368.00
2015-10-22 Lower Price Target HC Wainwright Buy $380.00 to $360.00
2015-10-21 Reiterated Rating RBC Capital Buy $450.00
2015-10-21 Reiterated Rating Piper Jaffray Hold $361.00 to $307.00
2015-10-20 Reiterated Rating JPMorgan Chase & Co. Overweight $414.00
2015-10-15 Reiterated Rating Jefferies Group Buy $348.00 to $322.00
2015-10-13 Reiterated Rating Raymond James Strong-Buy $404.00
2015-10-07 Reiterated Rating RBC Capital Outperform $450.00
2015-09-23 Reiterated Rating Oppenheimer Sector Perform
2015-09-23 Reiterated Rating Oppenheimer Holdings Inc. Sector Perform
2015-09-20 Reiterated Rating Cowen and Company Buy
2015-09-15 Lower Price Target Leerink Swann Outperform $464.00 to $425.00
2015-09-08 Initiated Coverage Jefferies Group Buy $348.00
2015-08-31 Initiated Coverage Raymond James Strong-Buy $400.00
2015-08-25 Reiterated Rating Cowen and Company Buy $494.00
2015-08-18 Reiterated Rating HC Wainwright Buy $380.00
2015-08-11 Reiterated Rating Deutsche Bank Buy
2015-08-11 Initiated Coverage HC Wainwright Buy $380.00
2015-08-11 Reiterated Rating Deutsche Bank AG Buy
2015-08-05 Reiterated Rating Cowen and Company Outperform $494.00
2015-07-27 Reiterated Rating JPMorgan Chase & Co. Buy $414.00
2015-07-27 Upgrade Sanford C. Bernstein Market Perform to Outperform $436.00 to $385.00
2015-07-27 Lower Price Target Argus Buy $450.00 to $360.00
2015-07-27 Reiterated Rating RBC Capital Outperform $525.00 to $450.00
2015-07-27 Downgrade Robert W. Baird Outperform to Neutral $480.00 to $316.00
2015-07-27 Reiterated Rating Morgan Stanley Overweight $520.00 to $426.00
2015-07-24 Downgrade BMO Capital Markets Outperform to Market Perform $511.00 to $360.00
2015-07-23 Reiterated Rating Leerink Swann Buy $512.00
2015-07-22 Reiterated Rating Cowen and Company Buy $494.00
2015-07-22 Reiterated Rating Deutsche Bank Buy
2015-07-22 Downgrade Robert W. Baird Outperform to Neutral $480.00 to $316.00
2015-07-22 Downgrade Piper Jaffray Overweight to Neutral $485.00 to $410.00
2015-07-21 Reiterated Rating Piper Jaffray Overweight to Overweight $485.00 to $410.00
2015-07-20 Boost Price Target Goldman Sachs Neutral $434.00 to $435.00
2015-07-18 Reiterated Rating JPMorgan Chase & Co. Buy
2015-07-14 Upgrade Bank of America Neutral to Buy $391.23 to $466.00
2015-07-12 Reiterated Rating JPMorgan Chase & Co. Buy $494.00
2015-07-12 Reiterated Rating Deutsche Bank Buy $460.00
2015-07-06 Reiterated Rating Morgan Stanley Buy
2015-07-02 Reiterated Rating Deutsche Bank Buy $460.00
2015-07-02 Reiterated Rating Piper Jaffray Buy $485.00
2015-07-02 Reiterated Rating JPMorgan Chase & Co. Buy
2015-06-25 Reiterated Rating Deutsche Bank Buy $460.00
2015-06-23 Set Price Target Morgan Stanley Buy $520.00
2015-06-11 Set Price Target Deutsche Bank Buy $460.00
2015-06-11 Lower Price Target Leerink Swann Outperform $532.00 to $512.00
2015-06-09 Initiated Coverage Guggenheim Neutral
2015-05-04 Reiterated Rating Piper Jaffray Overweight to Top Pick $500.00 to $485.00
2015-05-04 Reiterated Rating BMO Capital Markets Outperform $511.00
2015-04-27 Boost Price Target Argus Buy $440.00 to $450.00
2015-04-27 Reiterated Rating Nomura Neutral $401.00 to $442.00
2015-04-27 Lower Price Target Citigroup Inc. Buy $512.00 to $497.00
2015-04-27 Initiated Coverage Oppenheimer Market Perform
2015-04-27 Reiterated Rating Nomura Holdings Inc. Neutral $401.00 to $442.00
2015-04-26 Reiterated Rating JPMorgan Chase & Co. Buy
2015-04-24 Reiterated Rating Morgan Stanley Buy
2015-04-24 Set Price Target Piper Jaffray Buy $485.00
2015-04-24 Set Price Target BMO Capital Markets Buy $511.00
2015-04-15 Set Price Target JPMorgan Chase & Co. Overweight $420.00
2015-04-14 Set Price Target BMO Capital Markets Buy $511.00
2015-04-12 Reiterated Rating Piper Jaffray Buy $500.00
2015-04-09 Reiterated Rating Deutsche Bank Buy
2015-04-01 Reiterated Rating Barclays Overweight $500.00
2015-03-30 Boost Price Target BMO Capital Markets Outperform $495.00 to $511.00
2015-03-23 Boost Price Target Citigroup Inc. Buy $410.00 to $512.00
2015-03-23 Boost Price Target Morgan Stanley Overweight $418.00 to $525.00
2015-03-23 Downgrade Stifel Nicolaus Buy to Hold $451.00
2015-03-20 Set Price Target JPMorgan Chase & Co. Buy $420.00
2015-03-18 Reiterated Rating RBC Capital Buy
2015-03-15 Reiterated Rating JPMorgan Chase & Co. Overweight
2015-02-02 Boost Price Target Argus Buy $385.00 to $440.00
2015-01-30 Reiterated Rating Stifel Nicolaus Buy $376.00 to $443.00
2015-01-30 Boost Price Target Barclays Overweight $425.00 to $435.00
2015-01-30 Boost Price Target Citigroup Inc. Buy $383.00 to $410.00
2015-01-30 Boost Price Target RBC Capital Outperform $400.00 to $445.00
2015-01-29 Reiterated Rating Credit Suisse Outperform $400.00
2015-01-06 Initiated Coverage Barclays Overweight $425.00
2015-01-05 Set Price Target JPMorgan Chase & Co. Buy $407.00
2015-01-05 Downgrade Nomura Buy to Neutral $407.00 to $378.00
2014-12-03 Reiterated Rating S&P Equity Research Buy
2014-11-24 Initiated Coverage Leerink Swann Outperform $370.00
2014-11-19 Lower Price Target Credit Suisse Outperform $425.00 to $400.00
2014-10-23 Reiterated Rating Citigroup Inc. Buy $387.00 to $383.00
2014-10-22 Upgrade Robert W. Baird Neutral to Outperform $382.00
2014-10-22 Reiterated Rating RBC Capital Outperform
2014-10-01 Initiated Coverage Bank of America Neutral $371.00
2014-08-19 Initiated Coverage Stifel Nicolaus Buy $376.00
2014-08-18 Reiterated Rating Morgan Stanley Overweight $395.00
2014-07-29 Boost Price Target Argus Buy $360.00 to $385.00
2014-07-24 Reiterated Rating Deutsche Bank Buy $415.00 to $430.00
2014-07-24 Reiterated Rating Jefferies Group Buy $380.00 to $410.00
2014-07-24 Boost Price Target Nomura Buy $415.00 to $424.00
2014-07-09 Boost Price Target RBC Capital Outperform $325.00 to $375.00
2014-06-09 Reiterated Rating Morgan Stanley Overweight $395.00
2014-05-29 Upgrade JPMorgan Chase & Co. Neutral to Overweight $300.00 to $375.00
2014-05-27 Reiterated Rating Oppenheimer Market Perform
2014-04-28 Reiterated Rating Jefferies Group Buy $398.00 to $380.00
2014-04-24 Reiterated Rating Nomura Buy $415.00
2014-03-26 Initiated Coverage Morgan Stanley Overweight $395.00
2014-03-21 Reiterated Rating Deutsche Bank Buy
2014-03-19 Boost Price Target Stifel Nicolaus Buy to Buy $360.00 to $376.00
2014-03-07 Boost Price Target Barclays Overweight $325.00 to $352.00
2014-03-06 Upgrade BMO Capital Markets Market Perform to Outperform $286.00 to $422.00
2014-03-03 Boost Price Target Stifel Nicolaus Buy $330.00 to $360.00
2014-02-26 Boost Price Target Jefferies Group $358.00 to $398.00
2014-02-20 Boost Price Target Leerink Swann Outperform $322.00 to $351.00
2014-01-30 Boost Price Target Argus Buy $310.00 to $360.00
2014-01-30 Boost Price Target Brean Capital Buy $293.00 to $377.00
2014-01-28 Boost Price Target Deutsche Bank Buy $340.00 to $415.00
2014-01-27 Boost Price Target Canaccord Genuity Buy $291.00 to $355.00
2014-01-16 Boost Price Target Stifel Nicolaus Buy $296.00 to $321.00
2014-01-10 Boost Price Target Barclays Overweight $285.00 to $325.00
2014-01-08 Initiated Coverage Nomura Buy $368.00
2014-01-06 Boost Price Target Citigroup Inc. $338.00
2013-12-20 Boost Price Target RBC Capital Outperform $275.00 to $325.00
2013-12-12 Boost Price Target Argus Buy $280.00 to $310.00
2013-11-26 Initiated Coverage Piper Jaffray Overweight $331.00
2013-11-22 Boost Price Target Citigroup Inc. $320.00
2013-11-22 Boost Price Target Deutsche Bank $340.00
2013-11-22 Reiterated Rating Credit Suisse Positive
2013-10-30 Initiated Coverage FBR & Co. Market Perform $259.00
2013-10-29 Boost Price Target Oppenheimer Market Perform $207.00 to $235.00
2013-10-29 Boost Price Target Guggenheim Neutral $228.00 to $247.00
2013-10-29 Lower Price Target Canaccord Genuity Buy $292.00 to $291.00
2013-10-29 Boost Price Target BMO Capital Markets Market Perform $237.00 to $249.00
2013-10-29 Boost Price Target Barclays Overweight $240.00 to $262.00
2013-10-29 Boost Price Target Jefferies Group Buy $270.00 to $300.00
2013-10-28 Reiterated Rating Deutsche Bank Buy
2013-10-22 Reiterated Rating Wells Fargo & Co. Positive
2013-10-22 Reiterated Rating Wells Fargo Positive
2013-10-11 Reiterated Rating Jefferies Group Buy to Buy $266.00 to $270.00
2013-10-07 Boost Price Target Leerink Swann Outperform $286.00 to $300.00
2013-10-02 Reiterated Rating Credit Suisse Outperform $255.00 to $290.00
2013-09-18 Boost Price Target Goldman Sachs $220.00 to $240.00
2013-04-29 Reiterated Argus Buy $195 to $250
2016-07-13 Reiterated Rating Jefferies Group Buy
2016-06-30 Reiterated Rating Morgan Stanley Buy
2016-06-30 Reiterated Rating Jefferies Group Buy
2016-06-30 Reiterated Rating Leerink Swann Hold
2016-06-30 Reiterated Rating Bank of America Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
DENNER ALEXANDER J 0.20%  (461858) APRI / ARIA / BIIB / ENZN / MDCO / MSTX / VVUS /
SCANGOS GEORGE A Chief Executive Officer 0.02%  (54936) A / BIIB / EXEL /
Cox John EVP Pharmaceutical Oper & Tech 0.02%  (39045) BIIB / RGEN /
ALEXANDER SUSAN H EVP, Chief Legal Officer 0.01%  (24844) BIIB / IVC /
PAPADOPOULOS STELIOS 0.01%  (19946) BGMD / BIIB / EXEL / RGLS /
YOUNG WILLIAM 0.01%  (18509) BIIB / NSTG /
DORSA CAROLINE 0.01%  (18172) BIIB / ILMN / NTLA / PEG /
PANGIA ROBERT W 0.01%  (17707) BIIB /
Rowinsky Eric K 0.01%  (14144) BIIB / BIND / CNDO / MSTX / NAVB / STML / VSTM /
WILLIAMS DOUGLAS E EVP Research & Development 0.01%  (11817) ARRY / BIIB / IRWD / ONTY / RGLS /

Comments